thalidomide has been researched along with Glomerulonephritis in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Glomerulonephritis: Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In comparison with untreated mice, mice treated with 10 mg/kg of thalidomide monotherapy showed a significant decrease in proteinuria and significantly lower glomerular and tubular damage scores, comparable to 5 or 10 mg/kg of thalidomide plus PL or MMF plus PL." | 3.78 | Attenuation of nephritis in lupus-prone mice by thalidomide. ( Choi, KH; Kim, BS; Lee, SK; Lee, SW; Park, KH; Park, YB; Yang, J, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vertolli, U | 1 |
| Berno, T | 1 |
| Riva, M | 1 |
| Adami, F | 1 |
| Angelini, A | 1 |
| Calò, LA | 1 |
| Lee, SW | 1 |
| Park, YB | 1 |
| Yang, J | 1 |
| Park, KH | 1 |
| Lee, SK | 1 |
| Choi, KH | 1 |
| Kim, BS | 1 |
| Ramadan, KM | 1 |
| McKenna, KE | 1 |
| Morris, TC | 1 |
3 other studies available for thalidomide and Glomerulonephritis
| Article | Year |
|---|---|
A unique case of rapidly progressive glomerulonephritis following dexamethasone/bortezomib/thalidomide treatment for myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Fema | 2018 |
Attenuation of nephritis in lupus-prone mice by thalidomide.
Topics: Animals; Anti-Inflammatory Agents; Antigen-Antibody Complex; DNA; Dose-Response Relationship, Drug; | 2012 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bor | 2006 |